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Dr John G. Byrne (Nashville, Tenn). Craig, this is a fantastic
paper, superbly delivered. First, the results of the PARTNER trial
show amazing results in both the traditional AVR as well as the
TAVR groups. This well-designed and executed study documented
the results using a first-generation large device in very elderly sick
patients in which all adverse events were adjudicated by a CEC.
We all congratulate you, Craig, and your coinvestigators on this
historic trial. I have 3 questions.
Do you believe, as I do, that TAVR is here to stay? That open
AVR, traditional AVR, for senile calcific AS is perhaps an endan-
gered species? That in the future, open AVR will be reserved for
cases of endocarditis, root disease, bicuspid disease and the very
young? Given the amount of investment in this technology, both
financial and intellectual, isn’t it just a matter of time that TAVR
will become the procedure of choice for most senile patients
with calcific AS? Once SAPIEN and eventually CoreValve are ap-
proved by the Food and Drug Administration, how can surgeons
remain involved? Will cardiologists own the TF approach and sur-
geons own the TA approach? How do we stay involved in the TF
approach to this?
Dr Miller. Thank you, John, for those kind comments, which
are very germane. The first question is related at preventing abuse
and inappropriate use of TAVR. How do we prevent a runaway
train, as what has happened in Germany where now 20%-25%
or more of all AVRs are done percutaneously? This is a question
that ultimately is going to be dictated by the payors, and we
must also be mindful of the fact we don’t even have medium-842 The Journal of Thoracic and Cardiovascular Surgterm valve durability data yet. TAVR is not going to be cost effec-
tive and affordable if these valves don’t outlast most of the patients
they are inserted in. Now, ‘‘a goodly amount of time’’ is rather
short for a 95-year-old who is otherwise inoperable; it is com-
pletely different if you have a patient under 70 who has a very
low surgical risk and should have a 15-20 year life expectancy.
So we have to learn a lot more about the durability of percutaneous
bioprosthetic valves before they are used in younger, healthier
patients.
The proof of the pudding will actually be at the payor level; they
are the only ones who can enforce how TEVAR is applied. Person-
ally I am disappointed by what has happened in Germany. Here in
the United States, we have no idea once one or both of these de-
vices are approved by the FDA, but it is essential that a truly func-
tional integrated heart valve team make sure that these
complementary technologies—TAVR and surgical AVR—are
used appropriately. The heart valve team and the payors must
draw and enforce both lower and upper boundaries based on
open surgical AVR risk and life expectancy to ensure reasonable
use of TAVR. The lower boundary separates out the younger
healthier patients who should undergo open AVR even if they de-
mand a catheter percutaneous valve. The upper boundary is the
line between utility and futility where we must learn to say
‘‘No.’’ Many elderly, very sick patients with critical AS are dying
of a host of other serious medical problems, which in the PART-
NERTrial we call ‘‘Cohort C.’’ They have extreme co-morbidities
that overwhelm the potential benefits of TAVR; indeed, successful
TAVR in these Cohort C patients may only prolong their suffering,
and certainly is financially irresponsible for society.
I don’t think open surgical AVR is an endangered species. There
are many patients with severe AS out there we as surgeons have
never seen who potentially can benefit from either TAVR or
AVR, as the PARTNER Trial Cohort A results illustrate. Remark-
ably, in the PARTNER Cohort B (inoperable) New England Jour-
nal of Medicine paper in October 2010, the TAVR patients gained
1.9 quality years of life and it only cost $US55,000 per QUALY,
substantially less than the cost of dialysis per QUALY. So in the
inoperable cohort TAVR is cost effective and provides meaningful
rehabilitation. In the younger high risk operable patients, we have
to work together in the heart valve team to determine whether
TAVR or AVR offers the best option for each individual patient.
I repeat that these are complementary treatment methods, not com-
petitive. On the other hand, the transapical TA-TAVR approach
may possibly be an endangered species since direct aortic access
TAVR is now being explored in Europe; an upper mini-sternotomy
or even high anterior right thoracotomy is better tolerated than
a low left small thoracotomy, and there is no LV injury from the
TA purse-string sutures. In the “TF first” PARTNER Cohort A
trial, however, being judged a non–TF-TAVR candidate confered
a higher risk patient to begin with, and an elevated risk of late neu-
rologic complications.
We need strict patient selection. The way we and the other
PARTNER sites have found this to work well is to make the entire
process truly a team effort: In the preoperative decision-making
phase, during the procedure (a surgeon and interventional cardiol-
ogist alternate being the primary operator in TF-TAVR cases at
Stanford), and taking care of the patients after TAVR. Marty
Leon will tell you himself that it is easier, more fun, and quickerery c April 2012
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groin. So if you share the experience amongst your team and learn
from each other, it actually can be synergistic. This takes mutual
respect and mutual trust. It is very refreshing at this stage of my
career to see cardiovascular surgeons and interventional cardiolo-
gists set aside our parochial self-interests and egos in order to work
together for the patient’s benefit.
Dr Byrne. Twomore questions: Your study showed that the risk
of stroke continues well after the procedure. What is the mecha-
nism of continued stroke? Is it thrombus formation on the prosthe-
sis or does calcium continue to break loose? We surgeons
meticulously remove calcium, and in TAVR the calcium is left be-
hind. Is it thrombus or calcium or both or just heavy atherosclerotic
burden?
Finally, given that the risk of stroke continues most markedly
between 1 month and 1 year after surgery, what approaches do
you and your coinvestigators recommend to mitigate stroke?
What is the role of dual antiplatelet therapy and cerebral protection
devices?
Dr Miller. John, those are also very good questions. Given we
used a large, second generation TAVR device and there was a steep
learning curve in most of the PARTNER centers (only 6 of the 26
sites had any prior TAVR experience), there is ample room for im-
provement in patient selection, procedural expertise, and postoper-
ative patient management.
Even though we can’t prove it, the early neurologic events
within the first few days were probably due to particulate cerebral
embolization. There are several cerebral embolic protection de-
flectors and filters being developed that cover the arch vessels
and may reduce this intraprocedural neurologic event risk. For
the neurologic complications occurring later on, we have to re-
member that there is a high background neurologic event inci-
dence in these very old, sick patients that none of us can
change. It is unknown whether dual antiplatelet therapy or per-
haps even warfarin or other anticoagulant drug administered
over the long-term might reduce the late neurologic event rate.
In the TAVR patients, there are many nooks and crannies remain-
ing around the native calcified cusps which possibly may lead to
stagnant flow with eventual thrombus formation around the SA-
PIEN valve. I don’t believe embolization of calcific debris from
the aortic cusps is a major factor late postoperatively. More likely
micro-thrombus or platelet aggregates are forming in some of
these blind niches around the percutaneous valve, which later
can embolize to the brain. This is an open question, and an impor-
tant one; there is hope for improvement in late risk of neurologic
events as the antiplatelet and antithrombotic treatment regimens
are refined.
Thank you.
Dr IrvingKron (Charlottesville, Va).Craig, that was a great dis-
cussion, and I know that your heart and soul has been in this study.
What amazedmewas, frankly, the terrific results both for openAVR
and the percutaneous device in the patients who had the TF
approach. Do you think our risk adjustment scores are accurate?
Dr Miller. That is a great question, Irv. We must recall that the
STS scores have never been completely validated out at this ex-
treme end of the spectrum. The PARTNER cohort A patientsThe Journal of Thoracic and Caconstitute the highest STS risk decile, or the upper 10th percentile
of STS risk, and there just haven’t been enough of them in the STS
database to be certain. To answer your question, based on our re-
sults from these 26 institutions, the STS expected operative risk
score would appear to overestimate the observed open surgical
AVR risk, but we do not have any certainty this would be true
US-wide, from which the STS database comes. What would be
the result of such a trial in a real world situation? We do not
know, but were pleasantly surprised by the low death rates and neu-
rologic event rates in both the AVR and the TAVR groups. This is
especially true since data monitoring was prospective, monitored,
audited, and an external Adverse Events Committee was looking
over our shoulder. We couldn’t hide anything in this study even
if we had tried.
Dr Thomas W. Rice (Cleveland, Ohio). I found the mortality
cost data interesting. If you receive an open AVR, the observed
risk of death approaches the expected. If you receive a TAVR,
the observed risk of death does not approach the expected. Do
you have any insight?
Dr Miller. I do not know, Tom, but I speculate that perhaps the
neurologic events in the AVR group may have been more severe
cerebral insults such that more patients died right away. Or perhaps
it reflects a difference in the philosophy and aggressiveness of the
treating local physicians. Most late neurologic events happened far
away from the PARTNER TAVR centers; if a patient after TAVR
sustained a serious stroke the primary care physicians and the fam-
ily may have been more nihilistic, saying something like, ‘‘well,
we gave it the best shot, but let’s not let Granny suffer anymore.’’
We just don’t know, but it is interesting.
Dr Hartzell V. Schaff (Rochester, Minn). Craig, I want to fol-
low up on a question that John Byrne asked you, which had to
dowith antiplatelet therapy. I believe that the transcatheter patients
were all treated with dual antiplatelet therapy for 6 months or
a year. Do you think that the lack of that in a surgical group had
anything to do with the difference in the late risk of stroke?
DrMiller. That is an excellent question, Hartzell. Dual antipla-
telet therapy was recommended postoperatively for all the TAVR
patients, but it was only a recommendation. How strictly it was ad-
hered to and for how long is poorly characterized. One large enroll-
ing center had very few early neurologic complications in the
TAVR patients; they used aggressive antiplatelet and anticoagulant
therapy. Antiplatelet therapy for the AVR patients was left to the
discretion of the local surgeons, but I suspect most of them also re-
ceived at least aspirin postoperatively. We need to unravel this di-
lemma more completely in the future, but most PARTNER
investigators today now pay more assiduous attention to the anti-
platelet and anticoagulation regimen, even including starting anti-
platelet drugs immediately before the TF procedures. Since there
was no difference in neurologic complication risk between the
TAVR and AVR subgroups during the late hazard phase, I do not
think antiplatelet therapy had any influence on neurologic event
risk. Recall that late postoperatively the strongest determinant of
neurologic events was being judged to be a ‘‘non-TF candidate,’’
which cut equally across the TAVR subgroup as well as the AVR
subgroup. This is a patient-related and disease-related risk factor,
which cannot be changed.rdiovascular Surgery c Volume 143, Number 4 843
